[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"structural-heart-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:structural-heart-disease":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,42,55,86,109,132,155,183,202,232],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":25,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100053457","nhlbi-emory-advanced-cardiac-ct-reconstruction-100053457",false,"NCT05372627","NHLBI-Emory Advanced Cardiac CT Reconstruction","* INCLUSION CRITERIA:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n1. Male or female, aged \\>= 18 years\n2. Undergoing clinically-indicated contrast-enhanced time-resolved cardiac CT for structural heart disease.\n3. Ability of subject to understand and the willingness to sign a written informed consent document.\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n1. Unable to complete contrast-enhanced cardiac CT acquisition for any reason\n2. Unwilling to authorize future use of their imaging data for research","ALL","18 Years","100 Years",{"count":19,"type":20},1000,"ESTIMATED","OBSERVATIONAL","Background:\n\nDoctors use computed tomography (CT) to get detailed pictures of the heart. CT uses x-rays to gather raw data. Computers assemble this data to make the images doctors look at. A new computer technique can make higher resolution images from the same CT scans. In this natural history study, researchers will take normal CT images of the heart. They will compare those images to super high-resolution (super high-res) images made with a super-computer.\n\nObjective:\n\nTo improve the quality of heart CT scans by using new methods to create the images.\n\nEligibility:\n\nPeople aged 18 years or older who need a CT scan for heart disease.\n\nDesign:\n\nParticipants will have a normal CT scan. A substance will be injected through a tube in their arm. They will lie on a table in a large, donut-shaped machine. An X-ray tube will move around their body, taking many pictures.\n\nResearchers will use the normal CT scans to create super high-res images. They may do this at the NIH. They may also send the images to the company that made the CT scanner. Participants personal information will be removed before images are sent to the company. The personal information will be replaced by a code.\n\nThe super high-res images will be returned to the NIH.\n\nSome information will be collected from participants medical records. Researchers will compare the normal scans to the super high-res images.\n\nParticipants' own doctors will also have a chance to see the super high-res images.\n\nParticipants' CT pictures will be stored and used for future NIH research.",[24],"Structural Heart Disease",[26,27,28],"Heart Disease","Image","Natural History","NOT_YET_RECRUITING","2026-07-10",{"date":32,"type":33},"2026-07-13","ACTUAL",{"date":35,"type":20},"2026-07-16",{"date":37,"type":20},"2031-01-30",{"name":39,"class":40},"National Heart, Lung, and Blood Institute (NHLBI)","NIH",2,{"id":43,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":44,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":45,"conditions":46,"keywords":47,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":48,"lastUpdatePostDateStruct":49,"startDateStruct":51,"completionDateStruct":53,"leadSponsor":54,"locationsCount":41},"100467888",{"count":19,"type":20},"Background:\n\nDoctors use computed tomography (CT) to get detailed pictures of the heart. CT uses x-rays to gather raw data. Computers assemble this data to make the images doctors look at. A new computer technique can make higher resolution images from the same CT scans. In this natural history study, researchers will take normal CT images of the heart. They will compare those images to super high-resolution (super high-res) images made with a super-computer.\n\nObjective:\n\nTo improve the quality of heart CT scans by using new methods to create the images.\n\nEligibility:\n\nPeople aged 18 years or older who need a CT scan for heart disease.\n\nDesign:\n\nParticipants will have a normal CT scan. A substance will be injected through a tube in their arm. They will lie on a table in a large, donut-shaped machine. An X-ray tube will move around their body, taking many pictures.\n\nResearchers will use the normal CT scans to create super high-res images. They may do this at the NIH. They may also send the images to the company that made the CT scanner. Participants personal information will be removed before images are sent to the company. The personal information will be replaced by a code.\n\nThe super high-res images will be returned to the NIH.\n\nSome information will be collected from participants medical records. Researchers will compare the normal scans to the super high-res images.\n\nParticipants' own doctors will also have a chance to see the super high-res images.\n\nParticipants' CT pictures will be stored and used for future NIH research....",[24],[26,27,28],"2026-07-01",{"date":50,"type":33},"2026-07-02",{"date":52,"type":20},"2026-07-07",{"date":37,"type":20},{"name":39,"class":40},{"id":56,"slug":57,"hasResults":11,"nctId":58,"briefTitle":59,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":62,"targetDuration":4,"studyType":64,"phases":65,"briefSummary":67,"conditions":68,"keywords":69,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":85},"100588175","optimised-decrement-evoked-potential-deep-mapping-to-guide-ventricular-tachycardia-vt-ablation-in-patients-with-structural-heart-disease-vt-100588175","NCT06937983","Optimised Decrement Evoked Potential (DeEP) Mapping to Guide Ventricular Tachycardia (VT) Ablation in Patients With Structural Heart Disease VT","Opto-DeEP","Inclusion Criteria:\n\n* ≥18 years old\n* Patients with cardiac implantable electronic devices (CIED) (e.g. pacemakers, cardiac resynchronisation therapy (CRT) devices, implantable cardioverter defibrillator (ICD) devices)\n* Eligible for VT ablation as part of standard care (urgent or elective)\n* Ischaemic heart disease and prior myocardial infarction (MI) (using the international definition of MI: Q waves or imaging evidence of regional myocardial akinesis\u002Fthinning in the absence of a non-ischemic cause with documentation of prior ischaemic injury) OR other structural heart disease (such as: arrhythmogenic cardiomyopathy (ACM), or dilated cardiomyopathy (DCM), or hypertrophic cardiomyopathy (HCM), or sarcoidosis, or myocarditis).\n* Catheter ablation of VT ablation using Abbott intracardiac mapping catheter and Ensite intracardiac mapping system.\n\nExclusion Criteria:\n\n* Lacks capacity to provide informed consent\n* New York Heart Association (NYHA) class IV heart failure\n* Life expectancy of less than 12 months\n* Implanted with a ventricular assist device\n* Presence of mobile intracardiac thrombus\n* Reversible cause of VT\n* Women who are pregnant or nursing\n* Both mechanical aortic and mitral valves\n* Enrolment in a concurrent interventional clinical study that in the judgement of the investigator would increase risk to the patient or deem the patient inappropriate to participate in this study.",{"count":63,"type":20},77,"INTERVENTIONAL",[66],"NA","Ventricular tachycardia (VT) is a life-threatening heart rhythm disorder. Special pacemakers called implantable cardiac defibrillators (ICDs) help treat VT episodes, however they do not prevent the VT episodes from occurring. Catheter ablation for VT is a minimally-invasive and established procedure for preventing VT recurrence. This involves placing wires in the heart to find the diseased areas that are responsible for the VT episodes. The diseased areas are shown on computer-generated maps and are later removed via controlled tissue heating (ablation). A major challenge during the VT ablation procedure is locating the diseased area responsible for the VT episodes. Several methods have been described to locate the diseased heart area, however these methods are not always effective.\n\nIn this study, we aim to improve the identification of the diseased heart areas responsible for the VT episodes using a novel method. Our research group have developed, tested and peer-reviewed this improved method of locating diseased areas by looking for signals called decrementing evoked potentials (DeEPs). Ablation will target DeEPs shown on the computer-generated maps. We will assess if VT can be triggered at the end of the procedure. Patients will be monitored over 12 months to see if ablation of DeEPs leads to a reduction in VT episodes. We aim to recruit 77 patients with established heart disease of any cause, who have suffered VT episodes with ICDs. Suitable patients will be identified and recruited from inpatient and outpatient settings. A quality-of-life questionnaire will be completed by patients before and after the ablation procedure. The procedure will be performed as routine standard of care, in the cardiac catheter laboratory across multiple recruiting cardiac centres in the UK providing well established VT ablation service.\n\nOverall, this study will contribute towards developing refined VT ablation techniques, aiming to improve patient outcomes.",[24],[70,71,72,73],"Ventricular Tachycardia","Decrementing Evoked Potential mapping","Optimisation parameters","Clinical Applicability","RECRUITING","2026-04-09",{"date":77,"type":33},"2026-04-13",{"date":79,"type":33},"2025-04-11",{"date":81,"type":20},"2027-12-03",{"name":83,"class":84},"University Hospitals Coventry and Warwickshire NHS Trust","OTHER",1,{"id":87,"slug":88,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":90,"acronym":91,"eligibilityCriteria":92,"healthyVolunteers":11,"sex":15,"minAge":93,"maxAge":4,"enrollmentInfo":94,"targetDuration":96,"studyType":21,"phases":4,"briefSummary":97,"conditions":98,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":85},"100615700","the-asia-pacific-mitral--tricuspid-valve-in-valvevalve-in-ring-registry-100615700","NCT07296016","The Asia-Pacific Mitral & Tricuspid Valve-in-Valve\u002FValve-in-Ring Registry","AP ViV","Inclusion Criteria:\n\n1. Age ≥ 21\n2. Had at least one documented Mitral valve-in-valve\u002Fvalve-in-ring procedure done during the period of 1 Jan 2023 to current date. (Retrospective) OR Planned to undergo a Mitral valve-in-valve\u002Fvalve-in-ring procedure. (Prospective) OR Had at least one documented Tricuspid valve-in-valve\u002Fvalve-in-ring procedure done during the period of 1 Jan 2023 to current date. (Retrospective) OR Planned to undergo a Tricuspid valve-in-valve\u002Fvalve-in-ring procedure. (Prospective)\n\nExclusion Criteria:\n\n1. Active endocarditis\n2. Any other conditions which investigator deems unsuitable for participation.","21 Years",{"count":95,"type":20},15,"10 Years","A significant number of patients with severe mitral and tricuspid valve disease have been previously treated with either valve repair with annuloplasty rings or valve replacement with bioprosthetic\u002Fmechanical valves. Over time, these bioprosthetic valves and rings may fail resulting in recurrence of the valvular disease. The technical aspects of a re-do operation are complex and these patients are often times at high risk for repeat open surgery. The emergence of transcatheter options may provide a safer and less invasive alternative to open surgery. Majority of the data currently exist for Western cohorts with limited longer-term outcomes. Data on this therapy is particularly lacking in the Asia-Pacific region, especially important in the light of known differences in body habitus and size.",[24,99],"Mitral Valve Regurgitation","2025-12-16",{"date":102,"type":33},"2025-12-22",{"date":104,"type":20},"2026-01-05",{"date":106,"type":20},"2035-12-31",{"name":108,"class":84},"Prince of Wales Hospital, Shatin, Hong Kong",{"id":110,"slug":111,"hasResults":11,"nctId":112,"briefTitle":113,"officialTitle":113,"acronym":4,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":115,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":117,"conditions":118,"keywords":119,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":85},"100608480","improvement-of-an-algorithm-to-detect-structural-heart-murmurs-in-adult-patients-using-electronic-stethoscopes-100608480","NCT07202104","Improvement of an Algorithm to Detect Structural Heart Murmurs in Adult Patients Using Electronic Stethoscopes","Inclusion Criteria:\n\n* 18+ years old\n* Patient or patient's legal healthcare proxy consents to participation\n* Documented history of SHD\n* Undergoing (or has undergone, within 30 days) a complete echocardiogram\n* Willing to have heart recordings done with two different electronic stethoscopes\n\nExclusion Criteria:\n\n* Patient or proxy is unwilling\u002Funable to give written informed consent\n* Unable to complete a complete echocardiogram, or none recent completed within the last 30 days\n* No documented history of SHD\n* Experiencing a known or suspected acute cardiac event\n* Mechanical ventricular support (such as ECMO, LVAD, RVAD, BiVAD, Impella, intra-aortic balloon pumps, TAH, VentrAssist, DuraHeart, HVAD, EVAHEART LVAS, HeartMate, Jarvik 2000)\n* Unwilling or unable to follow or complete study procedures",{"count":116,"type":20},125,"The main objective of this study is to evaluate a machine learning model's ability to detect murmurs indicative of structural heart disease (\"structural murmur\") by analyzing phonocardiogram waveforms-and simultaneous electrocardiogram waveforms when available-in multiple auscultatory positions per subject. Diagnosis of structural murmur will be confirmed by gold-standard echocardiography and reviewed by an expert panel of cardiologists.",[24],[120,121],"structural heart disease","structural murmur","2025-09-23",{"date":124,"type":33},"2025-10-01",{"date":126,"type":20},"2025-09",{"date":128,"type":20},"2026-05",{"name":130,"class":131},"Eko Devices, Inc.","INDUSTRY",{"id":133,"slug":134,"hasResults":11,"nctId":135,"briefTitle":136,"officialTitle":136,"acronym":137,"eligibilityCriteria":138,"healthyVolunteers":139,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":140,"targetDuration":4,"studyType":64,"phases":142,"briefSummary":143,"conditions":144,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":85},"100565062","deployment-and-evaluation-of-artificial-intelligence-software-for-electrocardiogram-analysis-and-management-in-primary-care-100565062","NCT06637293","Deployment and Evaluation of Artificial Intelligence Software for Electrocardiogram Analysis and Management in Primary Care","DAISEA-ECG","Inclusion Criteria:\n\nFamily Physicians or Nurse Practitioners\n\nFamily physicians or nurse practitioners (NPs) practicing in one of the participating FMGs.\n\nFamily physicians who have given their free and informed consent. Patients\n\nAdult patients (18 years or older). Patients without follow-up in cardiology or internal medicine for cardiovascular issues (arrhythmia, heart failure, myocardial infarction, atherosclerotic coronary artery disease, valvular heart disease) or those who had a negative investigation in the past with no additional follow-up.\n\nECG\n\nAny 12-lead ECG performed with the MUSE GE 360 machine. ECG of adequate technical quality for interpretation (otherwise, it will be automatically rejected by the platform).\n\n\\-\n\nExclusion Criteria:\n\n* Family Physicians or Nurse Practitioners\n\nFamily physicians practicing exclusively in pediatrics (patients under 18 years old).\n\nFamily physicians unable to follow the project guidelines.",true,{"count":141,"type":20},2000,[66],"The DAISEA-ECG project aims to improve the diagnosis of heart diseases in primary care through the DeepECG platform, which combines ECG-AI and ECHONeXT algorithms. This study uses a stepped wedge design, where each Family Medicine Group acts as its own control. The FMGs will gradually transition from the control period (without AI recommendations) to the intervention period (with AI recommendations activated) in a randomized sequence.\n\nThe primary objective is to compare the sensitivity of family physicians in detecting cardiac pathologies, with and without the assistance of the DeepECG platform. Sensitivity is defined as the proportion of patients correctly referred to cardiology or for transthoracic echocardiography (TTE) among those who indeed required cardiovascular evaluation, as confirmed by an independent adjudication committee.",[145,24],"Primary Care Provider","2025-09-18",{"date":148,"type":33},"2025-09-19",{"date":150,"type":20},"2025-10-06",{"date":152,"type":20},"2027-03",{"name":154,"class":84},"Montreal Heart Institute",{"id":156,"slug":157,"hasResults":11,"nctId":158,"briefTitle":159,"officialTitle":160,"acronym":161,"eligibilityCriteria":162,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":163,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":165,"conditions":166,"keywords":169,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":177,"completionDateStruct":179,"leadSponsor":181,"locationsCount":85},"100601584","pressure-volume-loop-assessment-in-valvular-heart-disease-100601584","NCT07112391","Pressure-Volume Loop Assessment in Valvular Heart Disease","Invasive Hemodynamic Study of Structural Heart Diseases: A Monocentric, Non-Randomized Approach","VHD-PV-loop","Inclusion Criteria:\n\n* Adult patients (≥ 18 years old);\n* Patients with severe structural heart disease (meeting at least one of the following three criteria):\n\n  * Heart failure with moderate-to-severe or severe secondary mitral regurgitation\n  * At least severe tricuspid regurgitation\n  * Significant pulmonary valve stenosis and\u002For regurgitation\n\nExclusion Criteria:\n\n* Patients under legal guardianship or protection (e.g., guardianship, trusteeship, or any other legal protection measure);\n* Pregnant or breastfeeding women;\n* Vulnerable individuals (e.g., persons deprived of liberty, adults under legal protection);\n* Contraindication to right heart catheterization, including:\n\n  * Known proximal venous occlusion of the superior or inferior vena cava territory\n  * Presence of a mobile mass in the right heart chambers\n  * Significant tricuspid stenosis",{"count":164,"type":20},70,"The VHD PV loop study intends to assess invasive right ventricular to pulmonary artery (RV-PA) coupling in patients with valvular heart disease (VHD). Invasive RV-PA coupling is measured by using conductance catheters, the gold standard assessment for ventricular physiology. Several non-invasive parameters have been reported as surrogates for this complex physiological entity, but none of them has been tested against the gold-standard in this population. Based on this, our main objective is to assess the correlation of imaging derived RV-PA coupling in comparison to the invasive measurement.",[167,24,168],"Heart Failure","Interventional Cardiology",[170,171,172,173],"Chronic heart failure","Structural heart disease","Interventional cardiology","Multimodality imaging","2025-09-09",{"date":176,"type":33},"2025-09-16",{"date":178,"type":33},"2025-09-04",{"date":180,"type":20},"2027-09-04",{"name":182,"class":84},"Nantes University Hospital",{"id":184,"slug":185,"hasResults":11,"nctId":186,"briefTitle":187,"officialTitle":187,"acronym":188,"eligibilityCriteria":189,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":190,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":191,"conditions":192,"keywords":4,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":193,"lastUpdatePostDateStruct":194,"startDateStruct":196,"completionDateStruct":198,"leadSponsor":200,"locationsCount":85},"100591185","interventional-structural-registry---luebeck-100591185","NCT06977139","Interventional Structural Registry - LuEbeck","INSTYLE","Inclusion Criteria:\n\n* Structural heart disease\n\nExclusion Criteria:\n\n* Patients without consent\u002Finformation\n* Age ≤ 18 years",{"count":141,"type":20},"The aim of the registry is to investigate the effect of catheter-assisted procedures in the context of structural heart disease on clinical morbidity and mortality. Furthermore, the long-term prognosis of patients after a catheter-based procedure is to be evaluated.\n\nIn particular, the following parameters will be documented and the following questions discussed:\n\n* Underlying and concomitant diseases of these patients\n* Evaluation of the methods in relation to the respective disease\n* Safety - acute and long-term\n* Effectiveness - periprocedural, hospital and long-term course\n* Concomitant therapies",[24],"2025-05-08",{"date":195,"type":33},"2025-05-18",{"date":197,"type":33},"2021-09-11",{"date":199,"type":20},"2035-01-01",{"name":201,"class":84},"Prof. Dr. med. Ingo Eitel",{"id":203,"slug":204,"hasResults":11,"nctId":205,"briefTitle":206,"officialTitle":206,"acronym":207,"eligibilityCriteria":208,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":209,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":211,"conditions":212,"keywords":218,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":224,"lastUpdatePostDateStruct":225,"startDateStruct":227,"completionDateStruct":229,"leadSponsor":230,"locationsCount":85},"100577703","when-do-we-have-to-perform-cardiac-magnetic-resonance-in-patients-referred-for-premature-ventricular-complexes-by-their-cardiologists-100577703","NCT06801743","WHEN DO WE HAVE to PERFORM CARDIAC MAGNETIC RESONANCE in PATIENTS REFERRED for PREMATURE VENTRICULAR COMPLEXES by THEIR CARDIOLOGISTS","IRMESV","Inclusion Criteria:\n\n* patients with PVC who have performed ECG, Holter ECG and a CMR\n\nExclusion Criteria:\n\n* patient showing opposition tu use his personal data for the reseach,\n* patient unable to express his opposition,\n* patient deprived of liberty,\n* patient with language issues (speaking or writing French)",{"count":210,"type":20},200,"Premature ventricular complexes (PVC) are a common entity affecting approximatively 20% of the general population. It can be discovered incidentally on electrocardiogram (ECG) or associated with symptoms with a wide spectrum from palpitations, chest pain, to syncope.\n\nThe initial and non invasive assessment includes holter ECG monitoring, a transthoracic echocardiography (TTE) and an exercise stress test to rule out structural heart disease (SHD), and referred to as benign or \"idiopathic\" ventricular arrhythmias (IVA).\n\nHowever, these exams may fail to identify subtle myocardial abnormalities such as arrhythmogenic right ventricle dysplasia (ARVD), apical hypertrophic cardiomyopathy, healed myocarditis, ischemic or non-ischemic cardiomyopathies.\n\nCardiac magnetic resonance (CMR) imaging is the gold standard modality to assess regional and global ventricular function. It is also a unique modality to non-invasively detect myocardial edema, myocardial fatty replacement, focal and diffuse fibrosis and could potentially identify SHD in patients with PVC.\n\nHowever, the role of CMR is uncertain, recommended in case of atypical presentation or when the initial assessment can't exclude a cardiomyopathy (recommendations class IIa).\n\nThis study sought to determine whether and when CMR can be performed to provide diagnosis or prognostic information complementary to initial assessment in patients referred for PVC by their cardiologists.",[213,214,215,216,24,217],"Premature Ventricular Complexes","Ventricular Arythmias","Cardiac Magnetic Resonance Imaging","Focal or Diffuse Fibrosis","Idiopathic",[219,220,221,222,120,223],"premature ventricular complexes","ventricular arythmias","cardiac magnetic resonance","focal or diffuse fibrosis","idiopathic","2025-02-11",{"date":226,"type":33},"2025-02-13",{"date":228,"type":33},"2024-11-27",{"date":128,"type":20},{"name":231,"class":84},"Centre Hospitalier Universitaire, Amiens",{"id":233,"slug":234,"hasResults":11,"nctId":235,"briefTitle":236,"officialTitle":237,"acronym":238,"eligibilityCriteria":239,"healthyVolunteers":11,"sex":15,"minAge":240,"maxAge":241,"enrollmentInfo":242,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":244,"conditions":245,"keywords":257,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":262,"lastUpdatePostDateStruct":263,"startDateStruct":265,"completionDateStruct":267,"leadSponsor":269,"locationsCount":85},"100516173","prognosis-prediction-system-of-patients-with-cardiovascular-and-cerebrovascular-diseases-based-on-multi-omics-100516173","NCT06001073","Prognosis Prediction System of Patients With Cardiovascular and Cerebrovascular Diseases Based on Multi-omics","Prognosis Prediction System of Patients With Cardiovascular and Cerebrovascular Diseases Based on Multi-omics (PROSPECT): a National, Multicenter, Retrospective-prospective, Cohort Study","PROSPECT","Inclusion Criteria:\n\n* Patients who are regularly visited and followed up in the appropriate patient; department.\n* All patients met at least one of the following diagnostic criteria for cardiovascular and cerebrovascular diseases:\n* coronary artery disease group;\n* arrhythmia group;\n* heart valve disease group;\n* aortic dissection group;\n* cardiac masses group;\n* myocarditis group;\n* hypertension group;\n* cardiomyopathy group;\n* structural heart disease group;\n* ischemic cerebrovascular disease group;\n* hemorrhagic cerebrovascular disease group;\n* intracranial space occupying lesion group.\n\nExclusion Criteria:\n\n* Age \\\u003C3 years or \\>80 years old;\n* Pregnant and lactating women;\n* The patient declined to provide informed consent to participate in the study;\n* None of the above was met, but the patient was temporarily unable to sign the informed consent form due to coma and other reasons, and no legal representative signed it instead. Depending on the patient's condition, the patient may not be able to regain consciousness and sign the informed consent form.","3 Years","80 Years",{"count":243,"type":20},25000,"The etiology and specific pathogenesis of many cardiovascular diseases such as coronary atherosclerosis, cardiomyopathy, atrial fibrillation, and stroke are still unclear. Improving diagnosis and treatment, clarifying the pathogenesis, and providing scientific basis for the prevention and treatment are hot research topics in the study of cardiovascular and cerebrovascular diseases. This study intends to collect clinical data and biological specimen data of patients with cardiovascular and cerebrovascular diseases who meet the inclusion and exclusion criteria, and use multi-omics technology to deeply understand the pathogenic mechanisms of cardiovascular and cerebrovascular diseases and provide new ideas for specific and individualized treatment of patients with cardiovascular and cerebrovascular diseases, to construct early predictive prognostic models and provide a basis for effective treatment of clinical practice in patients with cardiovascular and cerebrovascular diseases.",[246,247,248,249,250,251,252,253,24,254,255,256],"Coronary Artery Disease","Arrhythmias, Cardiac","Heart Valve Diseases","Aortic Dissection","Heart Neoplasms","Myocarditis","Hypertension","Cardiomyopathies","Ischemic Cerebrovascular Disease","Hemorrhagic Cerebrovascular Disease","Brain Neoplasms",[258,259,260,261],"Cardiovascular diseases","Cerebrovascular diseases","Prognosis","Multi-omics","2024-07-10",{"date":264,"type":33},"2024-07-12",{"date":266,"type":33},"2022-12-05",{"date":268,"type":20},"2028-12-31",{"name":270,"class":84},"First Affiliated Hospital Xi'an Jiaotong University"]